Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase NA 1Phase 2/3 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 125OTHER 119NETWORK 49NIH 33OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Hypersensitivity 1

Interventions

Radiotherapy 10Cisplatin 10Carboplatin 7Capecitabine 6Neoadjuvant Therapy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Paclitaxel 4Cyclophosphamide 4Trastuzumab 3Tamoxifen 3Surgical Procedures, Operative 3Radiation 3Oxaliplatin 3Hydralazine 3Etoposide 3Drug Therapy 3pertuzumab 2pegylated granulocyte colony-stimulating factor 2palbociclib 2endostar protein 2Valproic Acid 2Tranexamic Acid 2Temozolomide 2TP protocol 2Saline Solution 2Radiotherapy, Adjuvant 2Proton Pump Inhibitors 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × OTHER_GOV × Dexamethasone × Clear all
NCT07413809 2026-02-17

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
92 enrolled
Plasma cell

Multiple Myeloma

NCT02349763 2020-10-23

DEPARO

Department of Medical Services Ministry of Public Health of Thailand

Phase 3 Completed
260 enrolled

Hypersensitivity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡